26 mar: Fastsættelse af kuponrente
26 mar: Åbning af ny fastforrentet obligation
26-03-2019 14:16:02

Lundbeck held its Annual General Meeting on 26 March 2019 at the company’s registered office

Valby, Denmark, 26 March 2019 - H. Lundbeck A/S (Lundbeck) announced today that the report by the Board of Directors was adopted and the annual report was approved at the annual general meeting.

The proposal to distribute a dividend of 61% of the net profit for the accounting year 2018, corresponding to DKK 12.00 per share, or a total dividend of DKK 2,389 million, was adopted.

Lars Søren Rasmussen, Lene Skole-Sørensen, Lars Erik Holmqvist, Jeremy Max Levin, Jeffrey Berkowitz and Henrik Andersen were re-elected to the Board of Directors. Immediately after the general meeting, the Board of Directors elected Lars Søren Rasmussen as Chairman and Lene Skole-Sørensen as Deputy Chairman of the Board of Directors.

The Board of Directors of Lundbeck will hereafter comprise:

  • Lars Søren Rasmussen (Chairman)
  • Lene Skole-Sørensen (Deputy Chairman)
  • Lars Erik Holmqvist
  • Jeremy Max Levin
  • Jeffrey Berkowitz
  • Henrik Andersen
  • Ludovic Tranholm Otterbein (employee representative)
  • Henrik Sindal Jensen (employee representative)
  • Rikke Kruse Andreasen (employee representative)

After having elected its Chairman and Deputy Chairman, the Board of Directors appointed members for the Audit Committee, the Remuneration and Nomination Committee and the Scientific Committee.

Henrik Andersen (chairman), Lars Søren Rasmussen and Lars Erik Holmqvist were elected as members of the Audit Committee. Lars Søren Rasmussen (chairman), Lene Skole-Sørensen and Jeffrey Berkowitz were elected as members of the Remuneration and Nomination Committee. Jeremy Max Levin (chairman), Lene Skole-Sørensen and Jeffrey Berkowitz were elected as members of the Scientific Committee.

The general meeting approved the remuneration for the Board of Directors for the year 2019.

Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as the company's auditor.

The proposal to give the Board of Directors authorization until the next annual general meeting to let the company acquire own shares of a total nominal value of up to 10% of the share capital was adopted. The purchase price for the relevant shares may not deviate by more than 10% from the price quoted on NASDAQ Copenhagen A/S at the time of the acquisition.

The proposal from the Board of Directors to adopt amended Remuneration Guidelines for the Board of Directors and Executive Management was adopted.

The proposal from the Board of Directors to remove the age limit for members of the Board of Directors and thereby amend Article 5.1 of the Company’s Articles of Association was adopted.

The proposal from the shareholder Kritiske Aktionærer (a Danish association), that if the return on equity in the company exceeds 7%, then the company must reduce the prices on the medicine sold by the company, was not adopted.

The Chairman of the general meeting was authorised to file for registration the resolutions passed at the general meeting with the Danish Business Authority.

No other business was on the agenda at the annual general meeting.

The Board of Directors

Lundbeck contacts

Investors:                                                                                 Media:

Palle Holm Olesen                                                                   Mads Kronborg

Vice President, Investor Relations                                           Senior Director, Corp. Communication

PALO@lundbeck.com                                                             MAVK@lundbeck.com

+45 30 83 24 26                                                                      +45 36 43 40 00

About H. Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.

Read more at www.lundbeck.com/global/about-us/progress-in-mind

Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programs and our products are available in more than 100 countries. Our research center is based in Denmark and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 18,1 billion in 2018 (EUR 2,4 billion; USD 2,8 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck and via LinkedIn.

Safe Harbor/Forward-Looking Statements

The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made taking into account past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.

Attachment

logo.jpg

Relateret indhold
29 maj - 
Onsdagens aktier: Genmab fik klø i uroligt marked
29 maj - 
Aktier/middag: Genmab og Ambu går til bunds i rødt mark..
29 maj - 
Aktier/åbning: Genmab sendes til bunds i C25 med lutter..
Relateret debat
09 maj - 
Så er vi ved at være ved opsamling omkring 268-270 opti..
08 maj - 
Nogen tjener man på, andre taber man lidt, har tjent 8,..
08 maj - 
Du går godt nok hurtigt ud af dine handler. Du må da ta..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Lars Christensens Verden - Episode 21: Hvis virksomhedernes betalingsevne svigter, knækker aktiemarkedet

14-06-2019 06:00:00
I episode 21 af podcastserien “Lars Christensens Verden” stilles der skarpt på asset allokering.Euroinvestors chefredaktør Lars Christensen har adm. direktør i og stifter af Copenhagen Allocation Partner (CAP) Morten Kongshaug med i studiet til en samtale om, hvilke værktøjer og indikatorer Morten Kongshaug benytter til at vurdere, om man skal være over- eller undervægt aktier i sin portefølje, og..

Fredagens aktier: Carlsberg sendt til bunds i overvejende rødt C25

14-06-2019 17:02:57
På en dag uden de helt store selskabsnyheder blev Carlsberg fredag sendt til bunds i et rødt C25-indeks, der samlet dykkede 0,7 pct. til 1125,94.Bryggeriaktien faldt 2,9 pct. til 880 kr., hvilket ifølge Martin Munk, senioraktierådgiver i Jyske Bank, kan skyldes, at salgstal fra et analysehus viste svaghed i Vesteuropa - særligt i Storbritannien og Italien.- Der er kommet nye salgstal fra Nielsen (..

Ørsted: Fransk konkurrent vinder havvindudbud i Frankrig

Relaterede nyheder
14-06-2019 12:29:09
Den statsejede franske energikoncern EDF er fredag blevet udråbt til vinderen af en udbudsrunde for havvind i Frankrig.Det oplyser den franske miljøminister, François de Rugy, fredag ifølge nyhedsbureauet Reuters.- EDF er blevet valgt, udtaler han ifølge nyhedsbureauet fredag.Dermed har det franske selskab, der har tyske Innogy og Enbridge som partnere, vundet retten til at opføre en havvindmøllep..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Lundbeck A/S 253,90 -1,6% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
15. juni 2019 23:21:44
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190527.1 - EUROWEB3 - 2019-06-15 23:21:44 - 2019-06-15 23:21:44 - 1 - Website: OKAY